A Phase I Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 With Concurrent Cisplatin and Radiation Therapy in Subjects With Locally Advanced Head and Neck Cancer.

Trial Profile

A Phase I Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 With Concurrent Cisplatin and Radiation Therapy in Subjects With Locally Advanced Head and Neck Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2015

At a glance

  • Drugs CUDC 101 (Primary) ; Cisplatin
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Orofacial cancer; Oropharyngeal cancer; Squamous cell cancer; Tongue cancer
  • Focus Adverse reactions
  • Sponsors Curis
  • Most Recent Events

    • 12 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 23 Oct 2013 Interim results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 28 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top